[Form 4] CalciMedica, Inc. Insider Trading Activity

Rhea-AI Filing Summary

CalciMedica, Inc. director, chief executive officer and 10% owner Rachel A. Leheny reported acquiring 186,729 shares of common stock at $0.8033 per share. The shares were obtained from the company under a Securities Purchase Agreement dated June 23, 2026 with a closing date of June 25, 2026, which was approved by an independent committee of the board. Following this transaction, she directly holds 317,655 common shares. She is also reported as indirectly holding 316,109 shares through Valence Investments SPV VI, LLC, 66,228 through Valence Investments SPV V, LLC, 356,989 through Valence Investments SPV IV, LLC, 3,500 through the Scheibler-Leheny Family Living Trust, and 1,000 through her spouse, while disclaiming beneficial ownership of the Valence entities’ holdings except to the extent of her pecuniary interest.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Leheny A. Rachel

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	186,729	$0.8033	$150K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 317,655 shares (Direct, null); Common Stock — 3,500 shares (Indirect, By Scheibler-Leheny Family Living Trust)

Footnotes (1)

1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 08:45 AM Accepted by SEC EDGAR 06/29/2026 - 08:45 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leheny A. Rachel

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST BLVD. S. #307

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		A(1)		186,729	A	$0.8033	317,655	D
Common Stock								3,500	I	By Scheibler-Leheny Family Living Trust
Common Stock								1,000	I	By Spouse
Common Stock								356,989	I	By Valence Investments SPV IV, LLC(2)
Common Stock								66,228	I	By Valence Investments SPV V, LLC(2)
Common Stock								316,109	I	By Valence Investments SPV VI, LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

2. The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.

	/s/ John Dunn, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CalciMedica (CALC) report for Rachel Leheny?

CalciMedica reported that CEO and director Rachel A. Leheny acquired 186,729 shares of common stock. The acquisition occurred at $0.8033 per share under a Securities Purchase Agreement, increasing her direct holdings to 317,655 shares after the closing on June 25, 2026.

How did Rachel Leheny acquire new CalciMedica (CALC) shares?

Rachel A. Leheny acquired the new CalciMedica shares from the company under a Securities Purchase Agreement dated June 23, 2026. The deal closed on June 25, 2026 and was approved by an independent committee of CalciMedica’s board of directors.

What are Rachel Leheny’s direct CalciMedica (CALC) share holdings after the Form 4?

After the reported transaction, Rachel A. Leheny directly holds 317,655 shares of CalciMedica common stock. This reflects the addition of 186,729 shares acquired at $0.8033 per share through the board-approved Securities Purchase Agreement that closed on June 25, 2026.

What indirect CalciMedica (CALC) holdings are associated with Rachel Leheny?

Indirect holdings associated with Rachel A. Leheny include shares held by Valence Investments SPV IV, V and VI LLCs, a family trust, and her spouse. She may be deemed to beneficially own the Valence LLC securities but disclaims beneficial ownership except for her pecuniary interest.

Was the CalciMedica (CALC) share acquisition by Rachel Leheny board-approved?

Yes. The Securities Purchase Agreement under which Rachel A. Leheny acquired 186,729 CalciMedica shares was approved by an independent committee of the company’s board. The agreement was dated June 23, 2026, with the transaction closing on June 25, 2026.